PIK3CD and breast carcinoma: Moreover, it has been demonstrated that AURORA kinase A, AURKA, sustains mTOR phosphorylation levels in PIK3CA-mutated breast cancer cells treated with a pan-PI3K inhibitor or the AKT inhibitor MK-2206 [274].